

The First European Nanomedicine Mentoring Program Launches a New Edition

Apply to boost your project development!

Paris, March 1st, 2017: The Nanomedicine Translation Advisory Board (NanomedTAB) offers since 2015 a free-of-charge mentoring program to **assess, advise and accelerate promising nanomedicine projects to the market**, based on the diverse experience of **top skills industry experts**. The objective? Help great projects and teams to get to commercial application faster and more reliably.

- ✓ 63 teams have already applied,
- ✓ from 16 countries in EU and beyond,
- ✓ half have been selected and are currently benefiting from coaching over time.

This fifth **edition** is now open to companies, public and private research entities, and other organisations leading nanomedicine innovative projects in Europe.

The **deadline** for applications is the **15^h of April 2017**.

Selected projects will be invited to attend the **next TAB-In Sessions**, a series of face to face meetings with experts to be held on the **31st of May 2017**, in **Gothenburg (Sweden)**, in the framework of the [NanoMed North Annual Meeting 2017](#).

Applications should be submitted through the following link: <http://www.nanomedtab.eu/?apply>.

Further information about the NanomedTAB and its experts can be found at <http://www.nanomedtab.eu>.

ends

Contacts

TAB Manager
Pedro SILVA
apsilva@tecminho.uminho.pt
Tel.: +351 253 510 596

ENATRANS Coordinator
Nicolas GOUZE
VDI/VDE-IT
Nicolas.gouze@vdi-vde-it.de
Tel.: +49 30 310078 209

ENATRANS Communication
Sarah GAUBERT
Violaine EMOURGEON
sarah.gaubert@nanobiotix.com
violaine.emourgeon@nanobiotix.com
Tel.: + 33 1 75 44 69 42

About the ENATRANS project <http://www.enatrans.eu>

Enabling NANomedicine TRANslation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to nanomedicine to successfully go through the different stages of development from the idea to the patients and improve global knowledge on nanomedicine. ENATRANS is led by a consortium

Initiative supported by:



of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft fur Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (Berlin, Germany).

About ETPN <http://www.etp-nanomedicine.eu/public>

Created in 2005, the European Technology Platform on Nanomedicine (ETPN), an initiative led by industry and set up together with the European Commission, is addressing the application of nanotechnology to achieve breakthroughs in healthcare. Its mission consists in building, shaping and supporting the European ecosystem of Nanomedicine. In 2015, the ETPN became an independent international Association under the French law 1901, with its Secretariat and headquarters located in Paris, France.

ETPN has developed solid and effective tools under the umbrella of the Nanomedicine Translation Hub aiming to select and help the development of the best innovative projects in Nanomedicine toward the clinic.

Initiative supported by:

